Market News AIOpen the app

RNA stock news · Atrium Therapeutics, Inc.

Stories about Atrium Therapeutics, Inc. (RNA) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for RNA

Follow Atrium Therapeutics, Inc. (RNA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RNA
Free on the App Store and Google Play, or on the web.
  1. Nov 12, 2026, 4:46 PM ET · Market

    Atrium Therapeutics shared its third quarter results, including a $50 million investment and news on its ATR 1072 trial.

    Good for RNA

    Atrium dosed a patient in its PRKAG2 syndrome trial and raised $50 million, extending its cash runway through 2028. This supports a stronger outlook.

  2. Sep 8, 2026, 1:35 PM ET · Market

    On Tuesday, 12 health care stocks saw big price changes during the day.

    Bad for RNA

    Atrium Therapeutics dropped 20.58% to $11.27, reflecting a clear negative price reaction during the day.